Spring 2027

Software Engineer Co-op

MedTech

Posted on 8/26/2026

Deadline 11/30/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$23.50 - $52.50/hr

+ One-time taxable housing stipend

No H1B Sponsorship

Cincinnati, OH, USA

In Person

Fully onsite in Cincinnati; transportation to and from the site is not provided.

Bachelor's, Master's

Category
Software Engineering (1)
Required Skills
Python
Software Testing
JUnit
C/C++
Linux/Unix

Get referred to Johnson & Johnson

See people who can refer or advise you

Requirements
  • Be enrolled in an accredited college or institution pursuing a Bachelor's or master's degree in computer science, computer engineering, or a related degree.
  • Have completed at least two semesters in school before the beginning of the co-op term and have sophomore or higher class standing.
  • Remain a student during the co-op term and not have a graduation date before the start of the co-op term.
  • Have a minimum GPA of 3.0.
  • Have direct software engineering experience using C, C++, and Python.
  • Have strong collaboration, technical leadership, and conflict resolution skills.
  • Demonstrate strong interest in healthcare.
  • Be legally authorized to work in the United States for the full duration of the co-op term.
  • Be permanently authorized to work in the United States and not require employment visa sponsorship, including H-1B or green card sponsorship, at the time of application or in the future.
Responsibilities
  • Design and develop product software that integrates with mechanical, electrical, and distributed computing systems.
  • Develop test tools for testing product software in an integrated environment.
  • Convert selected technical options into formal, testable written requirements.
  • Document designs and specifications in accordance with design control processes.
  • Conform to industry standards for medical device software, including IEC 62304.
Desired Qualifications
  • Experience with software design in Linux or a similar operating system.
  • Experience with software testing tools such as Google Test, NUnit, or JUnit.
  • Experience with Distributed Data Services, including RTI Connext, OpenDDS, MQTT, or similar distributed data-sharing libraries.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 sales rose 6.6% to $25.3 billion, and guidance increased.
  • Tremfya sales jumped 72.5% in Q2 2026, offsetting Stelara's biosimilar decline.
  • Rybrevant received FDA Priority Review August 2026 for head and neck cancer.

What critics are saying

  • The talc MDL still exceeded 63,000 claims in April 2026, and appeals continue.
  • J&J's $5.5 billion talc settlement covers existing ovarian cancer claims only, not future lawsuits.
  • Stelara sales fell 55% in Q2 2026, exposing pipeline execution pressure before 2027.

What makes Johnson & Johnson unique

  • J&J combines blockbuster drugs like Darzalex with MedTech breadth across hospitals and surgery.
  • IMAAVY gained FDA approval August 24, 2026, first therapy for warm autoimmune hemolytic anemia.
  • MONARCH QUEST 3 won FDA clearance August 17, 2026, advancing AI-guided bronchoscopy.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-2%
Yahoo Finance
Aug 25th, 2026
Louisiana jury awards $10M in talc case, J&J liable for $1.2M amid broader settlement talks

A Louisiana jury awarded $10 million in a mesothelioma case linked to talc exposure, assigning Johnson & Johnson over $1.2 million of the liability. The jury found J&J's talc products unreasonably dangerous and inadequately labelled regarding asbestos risks. The verdict is one of multiple talc trial losses for Johnson & Johnson alongside a proposed $5.5 billion settlement aimed at resolving approximately 76,000 ovarian cancer claims. If the settlement proceeds with sufficient claimant participation, it could reduce legal uncertainty. Despite the legal challenges, Johnson & Johnson reported record quarterly sales supporting its Innovative Medicine and MedTech divisions. The company's narrative projects $120.5 billion revenue and $28.6 billion earnings by 2029, requiring 7.2% yearly revenue growth. Ongoing talc verdicts and potential follow-on cases continue to shape perceptions of the company's legal risk alongside its expanding medicines and MedTech portfolio.

PR Newswire
Aug 24th, 2026
FDA approves IMAAVY as first-ever treatment for warm autoimmune hemolytic anemia

The US Food and Drug Administration has approved IMAAVY (nipocalimab-aahu) as the first treatment specifically for warm autoimmune hemolytic anemia in adults and children aged 12 and older. Johnson & Johnson announced the approval following FDA Priority Review. wAIHA is a rare, life-threatening condition where autoantibodies destroy red blood cells, causing severe anaemia and fatigue. Previously, only corticosteroids and immunosuppressants were available. The approval is based on the Phase 2/3 ENERGY study. Results showed approximately three times as many patients receiving IMAAVY achieved durable haemoglobin levels versus placebo by 24 weeks. Patients demonstrated a mean haemoglobin increase of 1 g/dL at Week 1. IMAAVY is an immunoselective FcRn blocker designed to reduce pathogenic IgG autoantibodies whilst preserving B-cell function. Common side effects included peripheral oedema, diarrhoea, and fever.

Yahoo Finance
Aug 24th, 2026
J&J rises 1.3% to $273 as investors seek stability amid tech selloff despite rich 32x earnings valuation

Johnson & Johnson shares rose approximately 1.2% to $273.31 on Monday as investors sought defensive stocks amid technology sector weakness. The pharmaceutical and medical-technology company reported second-quarter sales of $25.3 billion, up 6.6%, with adjusted earnings of $2.90 per share. The Innovative Medicine division posted 6.8% operational growth, whilst MedTech added 3.6%. Management raised its operating outlook, though acquisition-related costs affected reported profit guidance. However, the stock now trades at roughly 32 times earnings and sits 41.91% above its estimated fair value of $192.59. The company faces challenges including biosimilar competition for Stelara and uneven MedTech execution, with recent acquisitions expected to pressure near-term profits.

Yahoo Finance
Aug 24th, 2026
Pfizer and J&J navigate patent cliffs with newer drugs offsetting blockbuster losses

Pfizer and Johnson & Johnson are navigating patent cliffs as key drugs lose exclusivity, with their latest results showing differing stages of transition. Pfizer's revenue excluding COVID products grew 5% operationally in Q2 2026, with newer medicines like Padcev and Vyndaqel contributing. The company expects $9.7 billion in cost savings through 2029 to support margins during the transition. Johnson & Johnson's Innovative Medicine sales rose 7.8%, despite Stelara revenue declining 55%. Tremfya sales surged 72.5% to $2 billion, helping offset losses alongside growth from oncology and neuroscience products. Johnson & Johnson raised 2026 guidance, with reported sales expected to reach $101.1 billion and adjusted EPS of $11.68. Its MedTech division provides additional diversification that pure pharmaceutical company Pfizer lacks, suggesting Johnson & Johnson's transition is more advanced.

Yahoo Finance
Aug 21st, 2026
J&J's TECVAYLI plus daratumumab approved in Europe for relapsed/refractory multiple myeloma

The European Commission has approved Johnson & Johnson's TECVAYLI (teclistamab) combined with daratumumab for treating adults with relapsed or refractory multiple myeloma who have received at least one prior therapy. The approval, based on Phase 3 data, makes this immunotherapy doublet available as early as second-line treatment. The combination demonstrated statistically significant improvements in progression-free and overall survival versus standard care regimens. The drugs work complementarily, with daratumumab modulating the immune system to enhance T-cell fitness and activation, amplifying teclistamab's ability to kill myeloma cells. Over 90% of patients who were progression-free at six months remained so at three years. The treatment offers an off-the-shelf, steroid-sparing immunotherapy option for patients who often experience shorter remissions with each subsequent therapy line.